BURLINGTON, N.C.–Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH) announces that it is the first national clinical laboratory to offer HCV PCR testing using a newly FDA approved assay, the Roche COBAS® AmpliPrep/COBAS® TaqMan® HCV Test. This assay is intended to be used as an aid in managing HCV-infected individuals undergoing antiviral therapy. The assay can […]
HUNTINGTON BEACH, California and AMSTERDAM, The Netherlands, February 11 — Agendia, a world leader in molecular cancer diagnostics, today announced the appointment of Alan B. Carter as the company’s new Vice President of Global Business Development. “As we continue to grow as a global company, Alan’s appointment furthers one of our primary aims,” commented Dr. […]
Nanogen, Inc. (Nasdaq: NGEN), developer of molecular and rapid diagnostic products, announced today that it has signed a licensing and supply agreement with Scandinavian Gene Synthesis (SGS) for use of the Company’s proprietary MGB Probe technology and synthetic nucleic acid chemistries including dyes and quenchers for use in human in vitro diagnostic testing. Under the […]
Evogen, Inc., announced today the launch of its first molecular diagnostics and detection instrument providing innovative ultra-rapid PCR amplification and analysis. The compact EvoCycler™ HD12 is significantly more affordable than comparable instruments with numerous performance advantages. In conjunction with the highly sensitive and specific HyBeacons® PCR chemistry, recently licensed from LGC, Ltd., Evogen now offers […]
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, announced today it has signed a nonexclusive license with Roche Diagnostics for the use of Response Genetics’ patented PCR analysis to assess human epidermal growth factor type 2 (HER2) gene expression. The accurate measurement of HER2 gene […]
Company Provides Additional Details on SEQureDx Trisomy 21 Technology Performance Data SAN DIEGO–Sequenom, Inc. (NASDAQ: SQNM – News) today announced new data showing the discovery of DNA methylation markers for Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome) and Trisomy 13 (Patau syndrome) and identification of chromosome RNA-SNP markers for early detection of Trisomies 18 […]
Targets Diagnosis and Early Detection of Alzheimer’s and Parkinson’s Diseases OMAHA, Neb. and HOUSTON, Tex., Feb. 2, 2009 — Transgenomic, Inc. (OTC BB: TBIO.OB) and Power3 Medical Products, Inc. (OTC BB: PWRM) today announced they have finalized a transaction, pursuant to their signed Letter of Intent announced December 2, 2008 (see “Transgenomic Signs Letter of […]
Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash SAN DIEGO, Calif., Jan 30, 2009 — – Tepnel Brings Gen-Probe Current and Future Growth Opportunities in Transplant Diagnostics and Genetic Testing, Accelerates European Expansion Strategy – Gen-Probe Incorporated (Nasdaq: GPRO), a pioneer and leader […]
Sequenom, Inc. (NASDAQ: SQNM) today announced that it has named Allan T. Bombard, M.D., to the newly created position of Chief Medical Officer. Dr. Bombard will oversee Sequenom’s clinical and medical affairs, including clinical strategy, operations and clinical advocacy. “Allan has played an instrumental role in the development of our noninvasive prenatal diagnostic division, including […]
Collaboration with Leading Maternal-Fetal Medicine Physician Group Signifies Further Step Toward Commercializing Trisomy 21 Test SAN DIEGO–Sequenom, Inc. (NASDAQ:SQNM – News), today announced a collaboration with Obstetrix Medical Group, to provide the Sequenom Center for Molecular Medicine (SCMM) with samples for a study to further evaluate its novel, noninvasive prenatal test to assess Down syndrome […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
